WHO/UNICEF Zika Virus (ZIKV) Vaccine Target Product Profile (TPP)
Vaccine to protect against congenital Zika syndrome for use during an emergency
Overview
This TPP describes the preferred and minimal product characteristics for vaccines aimed at protecting against congenital ZIKV syndrome during emergency situations, such as the current or a future ZIKV outbreak. With that public health objective, this TPP is primarily aimed at vaccines for use in women of reproductive age, which may include pregnant women, with adolescent and adult males as a secondary target population if resources permit. The TPP has been drafted by a WHO working group of subject matter experts with diverse areas of expertise. It has undergone public consultation, and discussion in various fora. As our understanding of Zika epidemiology and pathology evolves rapidly, the TPP should be considered a living document. The first version was published in July 2016, and this revision incorporates considerations based on new data that has emerged in the last 6 months. It will continue to be adapted as knowledge on ZIKV evolves.